Key Highlights

  • Edesa Biotech (NASDAQ:EDSA) climbed 38.63% to USD 2.97 following a Japanese licence that delivers USD 12 million upfront, roughly 42% of its previous market value.
  • Immunovant gained 15.1% once 92.5% of people taking the 600 mg dose retained an ACR20 response at week 28, compared with 75.6% of placebo recipients.
  • Vir Biotechnology advanced around 13% once its Phase 3 hepatitis Delta study reached the main objective for 44% of participants, versus 0% in the comparison arm.
  • Roivant recorded USD 31.0 million in LISRAYA sales across five weeks, while Viridian disclosed a peak IgG reduction of 74% for VRDN-008.

1. Vir Biotechnology (NASDAQ:VIR)

On November 9, 2026, Vir Biotechnology (NASDAQ:VIR) advanced about 13% to USD 13.85, topping its previous 52-week peak of USD 12.45, following the success of its ECLIPSE 1 Phase 3 study in chronic hepatitis delta. Monthly injections of elebsiran and tobevibart were tested against deferred treatment in 124 patients. By week 48, 44% of those on therapy had hit the main target of undetectable virus together with normal liver enzymes, compared with 0% in the control arm, a p-value under 0.0001. Viral suppression alone was achieved by 79%, while enzyme normalization occurred in 53% versus 5%. Tolerability held up, with one grade 3 event that cleared and zero discontinuations. The program carries Breakthrough Therapy and Fast Track designations, ECLIPSE 2 and 3 readouts land in the first quarter of 2027, and a regulatory filing is slated for mid-2027. A late-stage success paired with a defined filing schedule makes this the most valuable catalyst on the list.

2. Immunovant (NASDAQ:IMVT)

Immunovant (NASDAQ:IMVT) climbed 15.1% to USD 35.15 from USD 30.53 after a favorable rheumatoid arthritis trial of IMVT-1402, an agent that blocks the FcRn receptor responsible for recycling antibodies. During the randomized Withdrawal phase, 92.5% of people on the 600 mg dose maintained an ACR20 response through week 28, versus 75.6% on placebo; the p-value was 0.0139. ACR50 rates came in at 80.0% compared with 56.1%. The 300 mg arm failed to separate from placebo at 75.0%, which makes the higher dose the clear signal. Serious adverse events were absent, side effects of grade 3 or above did not occur, and nobody stopped treatment because of adverse events in this window. Elsewhere the portfolio is being trimmed: a Sjogren's program is unlikely to move forward, cutaneous lupus has been dropped, and Graves' disease and myasthenia gravis readouts are set for 2027. Cash of USD 722.3 million covers the route to a Graves' launch. Roivant, which is the parent, also cited that result in its report.

3. Edesa Biotech (NASDAQ:EDSA)

Edesa Biotech (NASDAQ:EDSA) gained 38.63%, equal to USD 0.83, reaching USD 2.97 on November 9 after it granted Kyorin Pharmaceutical rights in Japan to its acute respiratory distress syndrome candidate. The company pockets USD 12 million at signing and may earn up to around USD 134 million across development, regulatory and sales hurdles, together with tiered royalties in the double digits. Size explains the importance here. The upfront sum is roughly 42% of the company's approximately USD 28.9 million Market Value at the previous close of USD 2.14, so the cash by itself reshapes funding for a micro-cap. Volume reached about 62.57 million shares against an average near 57,420, and intraday the stock touched USD 3.93 before easing back. Because the milestones are contingent and could stretch over years, the immediate worth lies in the cash rather than the headline total.

4. Roivant Sciences (NASDAQ:ROIV)

In quarterly results released on November 9, Roivant Sciences (NASDAQ:ROIV) disclosed USD 31.0 million in net product Revenue from LISRAYA over its first five weeks in US sales. Revenue for the period ending September 30 totaled USD 35.1 million, of which USD 4.2 million came from license and milestone payments. The launch figure is the chief catalyst since it offers an early gauge of Demand for brepocitinib, marketed as LISRAYA, a drug that also produced positive Phase 3 uveitis findings. Roivant additionally highlighted the favorable registrational-stage rheumatoid arthritis outcome for IMVT-1402 at Immunovant. Its Balance Sheet is substantial, holding about USD 4.2 billion in cash, equivalents and marketable securities, and it repurchased 2.1 million shares for roughly USD 72.5 million in the quarter. The stock rose following the update, but no confirmed figure for the gain was available.

5. Viridian Therapeutics (NASDAQ:VRDN)

Viridian Therapeutics (NASDAQ:VRDN) shared favorable Phase 1 findings on November 9 for VRDN-008, a subcutaneous FcRn blocker, with peak IgG lowered by 74%. That reduction held for eight weeks following the dose, and the half-life of 15 to 18 days runs as much as six times longer than first-generation Fc fragments. Such durability backs the goal of dosing once every eight weeks, a possible convenience edge in a competitive category. Overall tolerability was good: no serious adverse events, no dose-limiting toxicities, and albumin and LDL cholesterol were left intact. A registrational study in myasthenia gravis is scheduled for mid-2027 subject to regulatory input, and cash totaled USD 955.2 million at September 30. Because these results come from healthy volunteers at an early stage, this is the least developed catalyst on the list, and no share price change has been confirmed.

Where Things Stand

Vir Biotechnology's hepatitis delta Phase 3 success, with a filing targeted for mid-2027, makes it the most valuable of these five November 9 catalysts. Immunovant's 600 mg rheumatoid arthritis outcome points to the right dose and came with a 15.1% share gain, while Edesa's USD 12 million upfront payment is transformative relative to a Business valued near USD 28.9 million. The USD 31.0 million Roivant launch number and Viridian's 74% IgG reduction are earlier-stage signals. Subsequent results, filing schedules and 2027 launch trends will determine how much of that value endures.